Guaifenesin Dosing
For adults and children ≥12 years, the recommended dose is 200-400 mg orally every 4 hours (not exceeding 2.4 g/day), or 600-1200 mg of extended-release formulation every 12 hours (maximum 2.4 g/day). 1
Adult Dosing
- Immediate-release: 10-20 mL (200-400 mg) every 4 hours
- Maximum: 6 doses in 24 hours (2.4 g/day)
- Extended-release: 1200 mg (two 600 mg tablets) every 12 hours 2, 3
The extended-release formulation provides equivalent steady-state exposure to immediate-release dosing while reducing dosing frequency from every 4 hours to every 12 hours 3. This offers improved convenience and adherence without compromising efficacy.
Pediatric Dosing
Children 6 to <12 years: 5-10 mL (100-200 mg) every 4 hours 1
Children 2 to <6 years: 2.5-5 mL (50-100 mg) every 4 hours 1
Children <2 years: Consult a physician - insufficient safety data available 1
Maximum of 6 doses in any 24-hour period for all pediatric age groups 1.
Important Clinical Considerations
Formulation Options
- Oral solution: 100 mg/5 mL concentration 1
- Extended-release tablets: 600 mg 2, 3
- Immediate-release tablets: Various strengths available
Food Effects
Extended-release formulations can be taken with or without food, though Tmax is delayed in the fed state. However, AUC and Cmax remain equivalent, so food does not significantly impact overall bioavailability 3.
Dose Rounding
For pediatric liquid formulations, guaifenesin allows up to 15% dose rounding to facilitate practical home administration 4. This reflects its wide therapeutic index and low risk of dose-dependent adverse effects.
Safety Profile
Guaifenesin demonstrates excellent tolerability across age groups. In a post-marketing surveillance study of 552 adults, only 28 patients (5%) experienced treatment-emergent adverse events, all mild in severity, with no serious adverse events or deaths 2. The most common side effects are gastrointestinal (nausea, vomiting) and nervous system symptoms, all self-limiting 2.
Clinical Efficacy Caveat
While guaifenesin is FDA-approved and widely used, recent high-quality evidence questions its clinical benefit. A rigorous 2014 randomized controlled trial found no significant effect on sputum volume, sputum properties, or symptom improvement compared to placebo in acute respiratory tract infections 5. However, some studies in chronic bronchitis show more consistent benefits 6, 7.